Champions OncologyCSBR 64 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 151 Biotechnology companies, Champions Oncology ranks worse than 662250.99% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Champions Oncology is 0.00%.
The historical rank and industry rank for Champions Oncology's Dividend Yield % or its related term are showing as below:
CSBR's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Champions Oncology (NAS:CSBR) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Champions Oncology Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs ANVS, HYFT, GANX: Dividend Yield % Comparison
For the Biotechnology subindustry, Champions Oncology's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Dividend Yield % falls into.
Champions Oncology (CSBR) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #999999 out of 151 companies in the Biotechnology industry.
Is Champions Oncology's Dividend Yield % too high?
Champions Oncology's current Dividend Yield % is 0.00%. Based on the distribution chart, Champions Oncology ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Dividend Yield % compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #999999 out of 151 companies for Dividend Yield %. This places Champions Oncology in the lower half of its industry. The industry median Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.14 — trading 7.3% below its estimated fair value. The current Dividend Yield % is 0.00%. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.14 is trading 7.3% below its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Dividend Yield %: 0.00%
GF Value™: $6.62 vs. price of $6.14 (7.3% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
